Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1

Virology Journal

Volumn 4, Issue , 2007, Pages

  Ishii, Yoshiyuki ^a   Kondo, Kazunari ^a   Matsumoto, Tamae ^a   Tanaka, Keiko ^a   Shinkai Ouchi, Fumiko ^a   Hagiwara, Ken'ichi ^a   Kanda, Tadahito ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (N MALEIMIDO)BENZYL TRIMETHYLAMMONIUM IODIDE; 5,5' DITHIOBIS(2 NITROBENZOIC ACID); [2 (TRIMETHYLAMMONIUM)ETHYL]METHANETHIOSULFONATE BROMIDE; BIOTIN POLYETHYLENEOXIDE IODOACETAMIDE; CAPSID PROTEIN; CAPSID PROTEIN L1; CETUXIMAB; CYSTEINE; N ETHYLMALEIMIDE; STREPTAVIDIN; THIOL REAGENT; TRYPSIN; UNCLASSIFIED DRUG; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; THIOL DERIVATIVE;

ARTICLE; CELL MIGRATION; CONFORMATIONAL TRANSITION; ELECTRON MICROSCOPY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOFLUORESCENCE MICROSCOPY; MOLECULAR WEIGHT; SEDIMENTATION; VIRION; VIRUS INFECTIVITY; CELL LINE; CHEMISTRY; DRUG EFFECT; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; VIRUS CAPSID;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

BIOLOGICAL TRANSPORT; CAPSID; CAPSID PROTEINS; CELL LINE, TRANSFORMED; CYSTEINE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; SULFHYDRYL COMPOUNDS; SULFHYDRYL REAGENTS; VIRION;

EID: 37349036152     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-110     Document Type: Article

References (22)

1. Papillomaviruses and their replication. PM Howley DR Lowy, Fields Virology Philadelphia, Lippincott Williams&Wilkins, Lnipe DM, Howley PM, Forth 2001 2 2197 2229
2. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. C Volpers P Schirmacher RE Streeck M Sapp, Virology 1994 200 504 512 10.1006/viro.1994.1213 8178438
3. Classification of papillomaviruses. EM de Villiers C Fauquet TR Broker HU Bernard H zur Hausen, Virology 2004 324 17 24 10.1016/j.virol.2004.03.033 15183049
4. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. N Munoz FX Bosch X Castellsaque M Diaz S de Sanjose D Hammouda KV Shah CJ Meijer, Int J Cancer 2004 111 278 285 10.1002/ijc.20244 15197783
5. Papillomaviruses and cancer: from basic studies to clinical application. H zur Hausen, Nat Rev Cancer 2002 2 342 350 10.1038/nrc798 12044010
6. Efficient intracellular assembly of papillomaviral vectors. CB Buck DV Pastrana DR Lowy JT Schiller, J Virol 2004 78 751 757 14694107 10.1128/JVI.78.2.751-757.2004
7. Maturation of papillomavirus capsids. CB Buck CD Thompson YY Pang DR Lowy JT Schiller, J Virol 2005 79 2839 2846 15709003 10.1128/JVI.79.5.2839-2846.2005
8. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. PM Day CC Baker DR Lowy JT Schiller, Proc Natl Acad Sci USA 2004 101 14252 14257 15383670 10.1073/pnas.0404229101
9. Human alpha-defensins block papillomavirus infection. CB Buck PM Day CD Thompson J Lubkowski W Lu DR Lowy JT Schiller, Proc Natl Acad Sci USA 2006 103 1516 1521 16432216 10.1073/pnas.0508033103
10. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. RM Richards DR Lowy JT Schiller PM Day, Proc Natl Acad Sci USA 2006 103 1522 1527 16432208 10.1073/pnas.0508815103
11. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. DV Pastrana R Gambhira CB Buck YY Pang CD Thompson TD Culp ND Christensen DR Lowy JT Schiller RB Roden, Virology 2005 337 365 372 10.1016/j.virol.2005.04.011 15885736
12. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. K Kondo Y Ishii H Ochi T Matsumoto H Yoshikawa T Kanda, Viroloy 2007 358 266 272 10.1016/j.virol.2006.08. 037
13. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. K Slupetzky R Gambhira TD Culp S Shafti-Keramat C Schellenbacher ND Christensen RB Roden R Kirnbauer, Vaccine 2007 25 2001 10 10.1016/j.vaccine.2006.11.049 17239496
14. Mutational analysis of human papillomavirus type 16 major capsid protein L1: the cysteines affecting the intermolecular bonding and structure of L1-capsids. Y Ishii K Tanaka T Kanda, Virology 2003 308 128 136 10.1016/S0042-6822(02)00099-5 12706096
15. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. XS Chen RL Garcea I Goldberg G Casini SC Harrison, Mol Cell 2000 5 557 567 10.1016/S1097-2765(00)80449-9 10882140
16. Downregulation of protein disulfide isomerase inhibits infection by the mouse polyomavirus. J Gilbert W Ou J Silver T Benjamin, J Virol 2006 80 10868 10870 16928750 10.1128/JVI.01117-06
17. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. HJ Ryser EM Levy R Mandel GJ DiSciullo, Proc Natl Acad Sci USA 1994 91 4559 4563 8183947 10.1073/pnas.91.10.4559
18. Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein. S Jain LW McGinnes TG Morrison, J Vriol 2007 81 2328 2339 10.1128/JVI.01940-06
19. Progress in targeting HIV-1 entry. HJ Ryser R Fluckiger, Drug Discov Today 2005 10 1085 1094 10.1016/S1359-6446(05)03550-6 16182193
20. Carrageenan is a potent inhibitor of papillomavirus infection. CB Buck CD Thompson JN Roberts M Muller DR Lowy JT Schiller, PLoS Pathog 2006 2 e69 16839203 10.1371/journal.ppat.0020069
21. Mutagenesis and Synthesis of Novel Recombinant Genes Using PCR. NV Abbe JP Robert RP Larry, PCR PRIMER A Laboratory Manual Cold Spring Harbor Laboratory Press, Carl WD, Gabriela SD, 1995 603 612
22. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. A Shevchenko M Wilm O Vorm M Mann, Anal Chem 1996 68 850 858 10.1021/ac950914h 8779443